首页> 美国卫生研究院文献>Journal of Clinical Oncology >Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518

【2h】

Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518

机译：晚期类癌患者中奥曲肽+干扰素Alfa-2b与奥曲肽+贝伐单抗的III期前瞻性随机比较试验：SWOG S0518

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

PurposeTreatment options for neuroendocrine tumors (NETs) remain limited. This trial assessed the progression-free survival (PFS) of bevacizumab or interferon alfa-2b (IFN-α-2b) added to octreotide among patients with advanced NETs.

机译：目的神经内分泌肿瘤（NETs）的治疗选择仍然有限。该试验评估了晚期NET患者中加入奥曲肽的贝伐单抗或干扰素α-2b（IFN-α-2b）的无进展生存期（PFS）。

著录项

期刊名称 Journal of Clinical Oncology
作者
James C. Yao; Katherine A. Guthrie; Cesar Moran; Jonathan R. Strosberg; Matthew H. Kulke; Jennifer A. Chan; Noelle LoConte; Robert R. McWilliams; Edward M. Wolin; Bassam Mattar; Shannon McDonough; Helen Chen; Charles D. Blanke; Howard S. Hochster;
展开▼
作者单位

展开▼
年(卷),期 -1(35),15
年度 -1
页码 1695–1703
总页数 10
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献

1. Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518 [J] . Yao James C., Guthrie Katherine A., Moran Cesar, Journal of Clinical Oncology . 2017,第15期

机译：III阶段前瞻性随机比较试验奥德雷德雷德尔德加干扰素Alfa-2b与奥德雷德雷德州的糖尿病患者在先进的类癌肿瘤患者中：Swog S0518
2. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. [J] . Yao JC, Phan A, Hoff PM, Journal of Clinical Oncology . 2008,第8期

机译：针对晚期类癌肿瘤的血管内皮生长因子：贝伐单抗和聚乙二醇化干扰素α-2b对奥曲肽贮库的II期随机分配研究。
3. Lanreotide Depot/Autogel for Symptomatic Control of Carcinoid Syndrome (CS) in Patients With Neuroendocrine Tumors (NETs) Previously Responsive to Octreotide: Subanalysis of Patient-Reported Symptoms From the Phase 3 ELECT Study [J] . Pommier Rodney F., Fisher George A., Wolin Edward M., Pancreas . 2018,第3期

机译：甘油酯仓库/自凝胶症状综合征症状综合征（CS）患者，患者以前对octreotide响应的神经内分泌肿瘤（网）：患者报告的患者报告的患者的患者患者3阶段选择
4. Phase III Double-Blind Study of Depot Octreotide Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy: Results of North Central Cancer Treatment Group N00CA [O] . James A. Martenson, Michele Y. Halyard, Jeff A. Sloan, -1

机译：奥曲肽贮积液与安慰剂对预防盆腔放疗患者急性腹泻的三期双盲研究：北中部癌症治疗组N00CA的结果
5. Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518 [O] . James C. Yao, Katherine A. Guthrie, Cesar Moran, 2017

机译：III阶段前瞻性随机比较试验奥德雷德雷德尔德加干扰素Alfa-2b与奥德雷德雷德州的糖尿病患者在先进的类癌肿瘤患者中：Swog S0518

Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518

摘要

著录项

相似文献

相关主题

期刊订阅